Eli Lilly’s Orforglipron Shows Promise in Diabetic Patients

Eli Lilly’s oral GLP-1 receptor agonist, orforglipron, has regained momentum after new Phase III results in people with type 2 diabetes (T2D) and obesity. Data from the ATTAIN-2 trial (NCT05872620) showed significant weight loss and blood sugar reductions across all tested doses. Patients on the 36mg dose lost an average of 10.5% (22.9lb) of body weight over 72 weeks, while 12mg and 6mg doses led to 7.8% and 5.5% reductions, respectively, versus 2.2% with placebo. More than half of those on 36mg lost at least 10% of their body weight. Safety findings aligned with prior studies, with gastrointestinal issues being most common. Following the announcement, Eli Lilly’s share price rose nearly 6% during the trading day, reflecting renewed investor confidence. The results contrast with underwhelming ATTAIN-1 data in non-diabetic patients, while competitor Novo Nordisk remains ahead with its FDA-submitted oral semaglutide, expected to receive a decision in late 2025.

29-08-2025